Format

Send to:

Choose Destination
See comment in PubMed Commons below
Fertil Steril. 2000 Nov;74(5):984-6.

Depressive mood symptoms associated with ovarian suppression.

Author information

  • 1University of Oklahoma Health Sciences Center, Tulsa, 74135, USA. faye-biggs@ouhsc.edu

Abstract

OBJECTIVE:

To determine if sertraline is helpful in the management of depressive symptoms associated with ovarian suppression during GnRH agonist therapy as compared with a placebo-controlled group.

DESIGN:

Double-blind placebo-controlled prospective study design.

SETTING:

An obstetrics/gynecological office specializing in infertility in an academic environment.

PATIENT(S):

Premenstrual women with laparoscopically diagnosed endometriosis who required GnRH agonist therapy for treatment and did not have significant depressive or premenstrual mood symptoms at baseline.

INTERVENTION(S):

Participants were randomly assigned to either the sertraline treatment group or to the placebo group for the 3-month duration of the GnRH agonist therapy.

MAIN OUTCOME MEASURE(S):

The 21-item Hamilton Rating Scale for Depression (HRSD), which is an instrument designed to assess depressive symptomatology.

RESULT(S):

A Hotellings T(2) test for repeated measure analysis indicated a statistically significant (P<.05) between-group difference across time for the HRSD (T(2) = 13.3; F[3, 28] = 4.1; P=.02) with the sertraline treatment group manifesting significantly fewer depressive symptoms than the control group.

CONCLUSION(S):

The results indicate that sertraline is an effective option in the management of depressive mood symptoms associated with ovarian suppression during GnRH agonist therapy.

PMID:
11056245
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk